1449. Brostallicin

Nomenclature

CAS number: 203258-60-0
N-[5-[[[5-[[[2-[(Aminoiminomethyl)amino]ethyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-4-[[[4-[(2-bromo-1-oxo-2-propenyl)amino]-1-methyl-1H-pyrrol-2-yl]carbonyl]amino]-1-methyl-1H-pyrrole-2-carboxamide.
C30H35BrN12O5; mol wt 723.58.
C 49.80%, H 4.88%, Br 11.04%, N 23.23%, O 11.06%.

Description and references

DNA minor groove binder; bromoacryloyl derivative of distamycin A, q.v. Prepn: P. Cozzi et al., WO 9804524; eidem, US 6482920 (1998, 2002 both to Pharmacia & Upjohn). LC/MS/MS determn in plasma: S. Calderoli et al., J. Pharm. Biomed. Anal. 32, 601 (2003). Mechanism of action studies: C. Geroni et al., Cancer Res. 62, 2332 (2002); A. Fedier et al., Br. J. Cancer 89, 1559 (2003). Clinical pharmacokinetics and evaluation in advanced solid tumors: A. J. ten Tije et al., Clin. Cancer Res. 9, 2957 (2003); A. C. Lockhart et al., ibid. 10, 468 (2004). Review of clinical development: M. Broggini et al., Anti-Cancer Drugs 15, 1-6 (2004).

Chemical structure

Derivative

Hydrochloride.

Nomenclature

CAS number: 203258-38-2
PNU-166196.
C30H35BrN12O5.HCl; mol wt 760.04.
C 47.41%, H 4.77%, Br 10.51%, N 22.11%, O 10.53%, Cl 4.66%.

Properties

Yellow solid. uv max (95% ethanol): 312.0 nm (ε 48792).

Therapeutic Category

Antineoplastic.

Keywords

Antineoplastic